Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Treasury Shares (2020 - 2025)

Historic Treasury Shares for Abeona Therapeutics (ABEO) over the last 4 years, with Q3 2014 value amounting to $4000.0.

  • Abeona Therapeutics' Treasury Shares rose 2500.32% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year increase of 2500.32%. This contributed to the annual value of $3.3 million for FY2024, which is 3564.47% up from last year.
  • Abeona Therapeutics' Treasury Shares amounted to $4000.0 in Q3 2014, which was down 0.0% from $4000.0 recorded in Q2 2014.
  • Abeona Therapeutics' Treasury Shares' 5-year high stood at $4000.0 during Q2 2011, with a 5-year trough of $4000.0 in Q2 2011.
  • For the 4-year period, Abeona Therapeutics' Treasury Shares averaged around $4000.0, with its median value being $4000.0 (2011).
  • Over the last 5 years, Abeona Therapeutics' Treasury Shares had its largest YoY gain of 0.0% in 2012, and its largest YoY loss of 0.0% in 2012.
  • Over the past 5 years, Abeona Therapeutics' Treasury Shares (Quarter) stood at $97260.0 in 2021, then surged by 739.97% to $816958.0 in 2022, then skyrocketed by 199.67% to $2.4 million in 2023, then soared by 35.64% to $3.3 million in 2024, then increased by 23.03% to $4.1 million in 2025.
  • Its Treasury Shares stands at $4000.0 for Q3 2014, versus $4000.0 for Q2 2014 and $4000.0 for Q1 2014.